Table 3.
CSF DA and HVA moderate the effect of HIV on depressive symptoms, independent of psychosocial risk factors.
| DA Model | Unadjusted Model | AIC-adjusted Model | ||||
|---|---|---|---|---|---|---|
| Predictor | beta (SE) | 95% CI | p | beta (SE) | 95% CI | p |
| HIV | 3.5 (1.47) | 0.61, 6.39 | 0.018 | 1.80 (1.43) | −1.03, 4.62 | 0.212 |
| DA | 1.61 (1.07) | −0.50, 3.72 | 0.134 | 1.45 (1.00) | −0.52, 3.42 | 0.149 |
| HIV x DA | −3.15 (1.47) | −6.03, −0.26 | 0.033 | −2.79 (1.39) | −5.52, −0.05 | 0.046 |
| Lifetime MDD | - | - | - | 2.79 (1.45) | −0.06, 5.64 | 0.055 |
| Antidepressant use | - | - | - | 4.42 (1.52) | 1.41, 7.42 | 0.004 |
| Education (years) METH use disorder | - | - | - | −0.65 (0.34) | −1.31, 0.01 | 0.055 |
| Current (vs. none) | - | - | - | 11.45 (2.79) | 5.95, 16.94 | <0.001 |
| Lifetime (vs. none) | - | - | - | 4.24 (1.51) | 1.26, 7.22 | 0.006 |
| HVA Model | Unadjusted Model | AIC-adjusted Model | ||||
| Predictor | beta (SE) | 95% CI | p | beta (SE) | 95% CI | p |
| HIV | 3.52 (1.46) | 0.64, 6.4 | 0.017 | 1.8 (1.43) | −1.01, 4.62 | 0.209 |
| HVA | 1.55 (1.06) | −0.54, 3.64 | 0.146 | 1.19 (0.99) | −0.76, 3.14 | 0.232 |
| HIV x HVA | −3.68 (1.46) | −6.56, −0.81 | 0.012 | −3.20 (1.36) | −5.88, −0.53 | 0.019 |
| Lifetime MDD | - | - | - | 2.93 (1.44) | 0.09, 5.76 | 0.043 |
| Antidepressant use | - | - | - | 4.33 (1.52) | 1.33, 7.32 | 0.005 |
| Education (years) | −0.64 (0.33) | −1.30, 0.02 | 0.055 | |||
| METH use disorder | ||||||
| Current (vs. none) | - | - | - | 11.2 (2.77) | 5.74, 16.66 | <0.001 |
| Lifetime (vs. none) | - | - | - | 4.62 (1.48) | 1.71, 7.54 | 0.002 |
Note. AIC = Akaike information criteria; CI = confidence interval; DA = dopamine; HVA = homovanillic acid; MDD = Major Depressive Disorder; METH = methamphetamine; SE = standard error.